Skip to main content
رجوع
REGMF logo

RemeGen Co., Ltd.

جودة البيانات: 100%
REGMF
OTC Healthcare Biotechnology
KWD 10.00
KWD 0.00 (0.00%)
القيمة السوقية: 5.64B
نطاق اليوم
KWD 9.81 KWD 10.00
نطاق 52 أسبوعًا
KWD 1.50 KWD 12.53
حجم التداول
1,000
متوسط 50 يوم / 200 يوم
KWD 10.12 / KWD 8.12
الإغلاق السابق
KWD 10.00

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 8.2 0.3
P/B 2.8 2.9
ROE % 25.5 3.7
Net Margin % 21.8 3.8
Rev Growth 5Y % 22.1 10.0
D/E 1.3 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2029 KWD 0.000
KWD 0.000 – KWD 0.000
9.3 B 0
FY2028 KWD 4.453
KWD 1.894 – KWD 6.324
6.4 B 1
FY2027 KWD 1.303
KWD 0.555 – KWD 1.851
4.8 B 1

النقاط الرئيسية

Revenue grew 22.12% annually over 5 years — strong growth
ROE of 25.45% indicates high profitability
Net margin of 21.79% shows strong profitability
Negative free cash flow of -1.44B
P/E of 8.17 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 63.08%

النمو

Revenue Growth (5Y)
22.12%
Revenue (1Y)85.20%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
25.45%
ROIC11.32%
Net Margin21.79%
Op. Margin22.19%

الأمان

Debt / Equity
1.34
Current Ratio1.05
Interest Coverage0.00

التقييم

P/E Ratio
8.17
P/B Ratio2.84
EV/EBITDA10.74
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 85.20% Revenue Growth (3Y) 71.55%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 22.12% Earnings Growth (5Y) 25.72%
Profitability
Revenue (TTM) 3.17B Net Income (TTM) 690.24M
ROE 25.45% ROA 12.55%
Gross Margin 0.00% Operating Margin 22.19%
Net Margin 21.79% Free Cash Flow (TTM) -1.44B
ROIC 11.32% FCF Growth (3Y) N/A
Safety
Debt / Equity 1.34 Current Ratio 1.05
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio 8.17 P/B Ratio 2.84
P/S Ratio 1.78 PEG Ratio -0.37
EV/EBITDA 10.74 Dividend Yield 0.00%
Market Cap 5.64B Enterprise Value 7.55B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 3.17B 1.71B 1.08B 767.78M 1.42B
Net Income 690.24M -1.47B -1.51B -998.83M 276.26M
EPS (Diluted) 1.26 -2.73 -2.80 -1.88 0.57
Gross Profit 0.0 1.37B 822.99M 497.84M 1.36B
Operating Income 702.81M -1.37B -1.50B -1.05B 162.84M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 5.50B 5.53B 6.02B 4.16B 4.12B
Total Liabilities 3.51B 2.09B 1.04B 712.79M 523.07M
Shareholders' Equity 1.99B 3.44B 4.98B 3.45B 3.59B
Total Debt 2.67B 1.26B 165.04M 102.78M 197.69M
Cash & Equivalents 759.53M 709.07M 2.07B 1.76B 2.77B
Current Assets 2.29B 2.23B 3.21B 2.30B 2.98B
Current Liabilities 2.19B 1.14B 892.30M 616.40M 431.29M

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#193 of 670
45

النشاط الأخير

دخل Contrarian Investing (David Dreman)
Mar 24, 2026